Table 5 Completeness of medication-related information in discharge letter and community pharmacy and general practitioner medication overviews
From: Transition of care in stroke patients discharged home: a single-center prospective cohort study
Discharge letter overviews (n = 33) | Community pharmacy overviews (n = 33) | General practitioner overviews (n = 31) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Complete documentation n=, (%)a | Incomplete documentation n=, (%)a | No documentation n=, (%)a | Complete documentation n=, (%)a | Incomplete documentation n=, (%)a | No documentation n=, (%)a | Complete documentation n=, (%)a | Incomplete documentation n=, (%)a | No documentation n=, (%)a | Unknown n=, (%)a | |||||||||||
Total prescriptions, n = 243 | 150 | (62%) | 60 | (25%) | 33 | (14%) | 144 | (59%) | 56 | (23%) | 43 | (18%) | 95 | (39%) | 58 | (24%) | 63 | (26%) | 27 | (11%) |
Unchanged, n = 126 | 82 | (65%) | 23 | (18%) | 21 | (17%) | 92 | (73%) | 21 | (17%) | 13 | (10%) | 63 | (50%) | 24 | (19%) | 23 | (18%) | 16 | (13%) |
Started, n = 67 | 52 | (78%) | 13 | (19%) | 2 | (3%) | 43 | (64%) | 4 | (6%) | 20 | (30%) | 28 | (42%) | 7 | (10%) | 29 | (43%) | 3 | (4%) |
Change, n = 6 | 1 | (17%) | 4 | (67%) | 1 | (17%) | 2 | (33%) | 2 | (33%) | 2 | (33%) | 0 | 1 | (17%) | 2 | (33%) | 3 | (50%) | |
Switched, n = 20 | 8 | (40%) | 12 | (60%) | 0 | 7 | (35%) | 12 | (60%) | 1 | (5%) | 2 | (10%) | 11 | (55%) | 4 | (20%) | 3 | (15%) | |
Stopped, n = 24 | 7 | (29%) | 8 | (33%) | 9 | (38%) | 0 | 17 | (71%) | 7 | (29%) | 2 | (8%) | 15 | (63%) | 5 | (21%) | 2 | (8%) | |
Clinically relevant prescriptions, n = 121 | 86 | (71%) | 29 | (24%) | 6 | (5%) | 72 | (60%) | 23 | (19%) | 26 | (21%) | 53 | (44%) | 25 | (21%) | 34 | (28%) | 9 | (7%) |
Platelet aggregation inhibitors, n = 42 | 33 | (79%) | 8 | (19%) | 1 | (2%) | 27 | (64%) | 5 | (12%) | 10 | (24%) | 16 | (38%) | 6 | (14%) | 17 | (40%) | 3 | (7%) |
Oral anticoagulants, n = 5 | 4 | (80%) | 0 | 1 | (20%) | 3 | (60%) | 0 | 2 | (40%) | 3 | (60%) | 2 | (40%) | 0 | 0 | ||||
Antihypertensive drugs, n = 35 | 26 | (74%) | 6 | (17%) | 3 | (9%) | 27 | (77%) | 4 | (11%) | 4 | (11%) | 26 | (74%) | 3 | (9%) | 4 | (11%) | 2 | (6%) |
Statins, n = 32 | 21 | (66%) | 10 | (31%) | 1 | (3%) | 10 | (31%) | 12 | (38%) | 10 | (31%) | 6 | (19%) | 13 | (41%) | 10 | (31%) | 3 | (9%) |
Ezetimibe, n = 1 | 1 | (100%) | 0 | 0 | 1 | (100%) | 0 | 0 | 1 | (100%) | 0 | 0 | 0 | |||||||
Proton pump inhibitorsb, n = 6 | 1 | (17%) | 5 | (83%) | 0 | 4 | (67%) | 2 | (33%) | 0 | 1 | (17%) | 1 | (17%) | 3 | (50%) | 1 | (17%) | ||